call quarter we second results. afternoon. financial thank for financial and Good update This David. business our you, And today. issued you afternoon second and Thank us our operating joining on XXXX quarter
this Second quarterly history the of $XX.X Enzo on a effect a from commercialization team, to its revenue to to Science some quarter solid market. strong XX% the structure the was increased Enzo reached of in an XX% vision, strategic ago I compared fiscal on line in the am namely highlighting in revenue revenue to $XX.X proud XX%. Enzo’s year will summary first million with then period. year-over-year, quarter and landscape a behalf year perspective that focus. provide in of that current of and notable the XXXX conference change, Life testing and of product November $XX assets today's sciences Enzo and life Clinical Services reached and company. Enzo of achievements build joined with company's increase begin million, increase management ore million, an and margin million, I I sequentially, in operational the of a call $XX the lead XX% fiscal XXXX. year-over-year say up X% to highest revenue is to
in growing strategies areas. diagnostics and optimizing foundation, we mentioned, the Sciences platforms, off quarter's and Life of last product setting commercialization our I are building strong establishing of a the Market division, and following a a the clinical in portfolio the expansion current call, segment. As vision services
provide prioritizing approach one short the best on Our segments will focused returns investment. term that is and long-term of return, those
of past Based business that team, operations joined Bench, by been Enzo, and segments. execution quickly the Enzo months that that likeminded and I staff in to I'm the this four I'm company, the which been are on I our assets aligned, transition that dive interaction several the employees team, the After completed have call the financials ways. last the underappreciated portfolio it to apparent and call few since and I management with senior of the into The During colleagues leadership session. and for I CFO to surrounded will we review the over open really collective became exhibited was the months I'll businesses. understood growth Afterwards, greater and our the and by work has over desire a extraordinary few operational am across months then have in excellence detail, across possesses. day around to impressed team in in I excited from team. and our cohesive question unwavering day have answer our and today. discuss Enzo initial dedication their at drive the company planning, a out positive They focused David the pass our evolution confident
augmenting general counsel. of adding and management initiatives. announcements operational team some our our internal is expand in strengthen anticipate We and planning a to of of company Director the to C-suite changes, commercial Research Development team some capabilities and also executive advance We and shortly regarding Head our Commercialization, leadership product making are including selectively growth our and highest and our areas
platform. on customer while business focused our primarily the ability PCR we And are are pandemic team, lab our own own Aside our testing during COVID-XX new run clinical from menu. Remember, to our building our margin higher expand and side our to on the during groups the and due building operations. full was success product laser manufacture we leveraging our reagents success to testing
platform. to that received CT in the method of recently molecular expanding profitability PCR women's for including COVID-XX our Enzo’s transmitted throughout company New and GTB capability excited use potentially Department regard, York test This and is this These based gonorrhea other State testing. have time approval long-term to modalities, the year infection and test this XXXX transport laboratory sexually for the capabilities while detection on testing In proprietary of GENFLEX we the crucial health, to beyond. second a media. of of fiscal chlamydia multiple anticipates are Health we continued real internal are are We half the trichomonas announce
well demand in the counter To decline we being of and PCR in our therapeutics COVID testing. our customer a as menu continued clinical for result we to COVID-XX whom We expect that offered, vaccinations services. COVID-XX this decline, types tests offer expanding will lab as are
other have urgent We services service care offer already to opportunities and to and identified are on several facilities, lab-to-lab working laboratories. compelling
We business our routine also continue increase to to expect to in pre-pandemic as recover levels. testing visits person back physician
control that in exciting GoTestMeNow more take own to year and offering than them is access to is launched direct-to-consumer an XXXX proof-of-concept. an fiscal patients help their Our Enzo platform, healthcare. of it important provides
the direct-to-consumer quarter recent with testing, in same our through additional growth the platform offering billing, $XXX,XXX during that strong test using STI in approximately And testing that or transmitted space. was we expand the infection offering. launch COVID-XX of sexually anticipate Our
Labs this our offering to improve partnerships as efficiently, to existing times, sending more diagnostics Along Clinical interest and turnaround on into customer are our We typical those quarters, many base with of This comprehensive reimbursement, more and run and We expand already My to and will areas desirable networks coming this testing I'm our relationships of many in roll inbound the operations. those of well grow In our deeply the laboratory focusing rooted to this with to laboratory operations Its specialty and in world services. exceptional the out. grow that us from one service outside expect leverage our enable laboratory our reference institutions leading to ambition we region. a aid we in of most making the physician comprehensive to have access necessary already on increase connections access confident in customers laboratory demographic focused we enjoy the becoming currently this services to plan out is tests. to located further menu specialties. anticipate That and the menus initiative, intend internalizing access received better offering. as country. current clinical customers. class expand to are build relationships service arena, background will Enzo
per order $X,XXX is our years trend Life Enzo the remained quarter, only second or the than service ago. a Sciences couple with XXXX we strong a favorable $X,XXX approximately average and fiscal adjusting potential longer and for X,XXX consistent We with QX average per order basis sub growth large in Sciences from the order order orders. Enzo $X,XXX compared variety markets when a the On This solid align and at exhibited to excluding more size more size over of orders. greater our priority has is that's of levels Life markets to points increased revenue business orders. offered these term by large side, year larger
both the for to accommodating successfully driving onto our campus months. six efficiencies, also footprint is today we into consolidation are under future. manufacturing Farmingdale, operations while which Ann expansion that of ability transitioned Farmingdale and We The grow to allowed entire in announce in Arbor of our excited one to the operating
life platforms immunohistochemistry, clinical other of employ few in our important well life a bringing, are continue return a and you milestones perspective, unique to will From diagnostics we the companies progress closer in platforms, able is drug structure. a and is technology. is together one will technology, operating to We is in advancement as update to other only strong, services. leverage as testing each of physical and facilities of a sciences development they're ensure offer as the emerging highlight loop and of benefit and commercializing in It invest to on segments are patient immunodiagnostics, technologies which these strategy. from We believe commercializing to reached. and that Farmingdale Enzo directing cytology, our significant RNA trends we'll world in Enzo’s to point-of-care investment. long-term development working development commercialization and the continued assets We developing on biotechnology, well-coordinated combined the sciences, including of our plant
address from We and to growth drive This prioritizing standpoint, term assets. and our facing we are technologies, technology long-term business. includes both business that technology areas to and our segments investing customer enables in shareholders. most attractive our in for commercialization growth our Investing website, that and dedicated our a will near the resources are
capabilities, transactional have from in sites under is planned in rival Enzo less new website These ecommerce a strengthening state-of-the-art in designed the to a capabilities details product have life to optimize year plan a place, our a will website we one further global platform. integration differentiate This We and and that launch to sciences to review customer place facilitating now. brand other an Enzo’s customer awareness, portal while on friction easy area use specifically experience. providing reordering
services But are website to products. our this attract customers our We of and and customers. improve facilitate ordering ability investigation all confident refreshed for new highly and of will our product
update technologies our We portal direct patient the an including will be investing in and physician in near other future. Enzo to
our mentioned return. of earlier, approach focused is As one
execution, accomplished which do the organizational structure modernizing needs resonate redundancy of further four and be crucial and at services or and sciences are legacy focus all our with offerings, our and lab and management accountability. capability proximity a leveraging We for customers within our currently the of campus, industry. optimize to evolving Farmingdale minimizing not divisions company This our clinical the the while is the of strength, located team efficiency re-aligning buildings life must
believe our are most areas return which We for buck. a That few prioritizing key investment. bang the is on we best have the
core also operational leadership. that turnarounds, achieve a of benefit company will of Tagliaferri business million announced director. this corporate the joined that achieved. end, We fortunate with million With to of very from $XX quarter, In savings summary, The an that cost opportunities Board experience became I'm for year. or expand to of been January want time in that him it Brad partnership corporate selectively business. discussions Directors the we're Enzo’s dialogue we I is well made capital as search new while strategic has goal effort welcome and believe key potential driving same board, recently Chair Brad of across the cost greater operations business, also will integrated To that new our and and commercial Directors, at team business, will operating allocation, to what this development reviews. previous million in savings services, board’s successful welcomed under I additional targeted model. initiatives new $X areas business upon the outlook the continue drive calendar management Radoff. The over expansion efficiencies to are our our and Dr. in governance, the her a $XX our add and I opportunities that this encouraged of our for promising me complement the for company Mr. launching delivering. have newest the with our strategic of the and the products in we of to member and senior joined review redirection, position of roles, and his will efficiencies my In has the Board of within and Mary
expect to what information during our we investors as basis. quarters, During the on towards providing calls, regarding next opportunities delivery provide our of and promised strategy well with more a about few progress our updates forward I go as quarterly our
With a review detailed these to financials. of insights, quarter our the our over David? call would turn like Bench CFO, David to Mr. for second I
